MedTrace Logo

Nebulized Heparin for COVID19-associated Acute Respiratory Failure

NCT04842292 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2022-10-18

Study results available
· View outcomes & findings →

Summary

The objective of the current study is to investigate the utilization of nebulized heparin to circumvent pathologic changes in COVID-19 and prevent harmful effects possible with systemic anticoagulation.

Conditions

  • Covid19

Interventions

DRUG

Heparin

Nebulized heparin 25,000 units every 6 hours

DRUG

Placebo

Sodium chloride 0.9% every 6 hours

Sponsors & Collaborators

  • Brittany Bissell

    lead OTHER

Principal Investigators

  • Brittany D Bissell · University of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-20
Primary Completion
2021-09-04
Completion
2021-09-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04842292 on ClinicalTrials.gov